Innovations in Understanding the Biology of Cervical Cancer

Cancer

Volumn 98, Issue 9 SUPPL., 2003, Pages 2064-2069

  Wolf, Judith K ^a   Franco, Eduardo L ^b   Arbeit, Jeffery M ^c   Shroyer, Kenneth R ^d   Wu, Tzyy Choou ^e   Runowicz, Carolyn D ^f   Tortolero Luna, Guillermo ^a   Herrero, Rolando ^g   Crum, Christopher P ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^g Proyecto Epidemiologico Guanacaste   (Costa Rica)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cervical cance; Cervical cancer; Human papillomavirus; Telomerase; Vaccine

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; ESTROGEN; ORAL CONTRACEPTIVE AGENT; TELOMERASE;

CANCER INVASION; CANCER SCREENING; CONFERENCE PAPER; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HIGH RISK POPULATION; HUMAN; INFECTION RATE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0142181126     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11682     Document Type: Conference Paper

References (33)

1. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80:3812-3815.
2. Kremsdorf D, Jablonska S, Favre M, Orth G. Biochemical characterization of two types of human papillomaviruses associated with epidermodysplasia verruciformis. J Virol. 1982;43:436-447.
3. Crum CP, Ikenberg H, Richart RM, Gissman L. Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med. 1984;310:880-883.
4. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
5. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
6. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415-1423.
7. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001; 183:8-15.
8. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
9. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92:464-474.
10. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica. 1999;6:223-233.
11. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis. 2000;27:79-86.
12. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997;1:362-375.
13. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
14. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:945-951.
15. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
16. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001;84: 1219-1226.
17. Jarboe EA, Liaw KL, Thompson LC, et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene. 2002;21:664-673.
18. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000;60:1267-1275.
19. Jin L, Qi M, Chen DZ, et al. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res. 1999;59:3991-3997.
20. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A. 1996;93:2930-2935.
21. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol. 2001;8:83-92.
22. Wang TY, Chen BF, Yang YC, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol. 2001;32:479-486.
23. Cviko A, Briem B, Granter SR, et al. Adenoid basal carcinomas of the cervix: a unique morphological evolution with cell cycle correlates. Hum Pathol. 2000;31:740-744.
24. Frost M, Bobak JB, Gianani R, et al. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am J Clin Pathol. 2000;114:726-734.
25. Shroyer KR, Thompson LC, Enomoto T, Eskens JL, Shroyer AL, McGregor JA. Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix. Am J Clin Pathol. 1998; 109:153-162.
26. Chen C, Wang T, Hung C, Pardoll DM, Wu T. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 2000;18:2015-2022.
27. Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol. 2001;75:9654-9664.
28. Cheng WF, Hung CF, Hsu KF, et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/ lysosomal compartments. Hum Gene Ther. 2001;12:235-252.
29. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. 1999;6:1972-1981.
30. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999;10:2727-2740.
31. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108:669-678.
32. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility Class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
33. Crum CP. The beginning of the end for cervical cancer? N Engl J Med. 2002;347:1703-1705.